A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma Meeting Abstract

  

Authors:	Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
Abstract Title:	A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Meeting Title:	2025 ASCO Gastrointestinal Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	4 Suppl.
Meeting Dates:	2025 Jan 23-25
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-02-01
DOI:	10.1200/JCO.2025.43.4_suppl.TPS515
PROVIDER:	EBSCOhost
PROVIDER:	cinahl plus with full text
DOI/URL:	https://research.ebsco.com/linkprocessor/plink?id=67ed2ec1-db17-3347-b08b-fe01d61200cd
Notes:	Meeting abstract: TPS515 -- Source: CINAHL Plus with Full Text

https://synapse.mskcc.org/synapse/works/has_related_data_chk/222544